Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jordyn O'Leary

Physician Assistant Scranton, PA Physician Assistant

NPI 1265907851 CMS profile 5695019

1405 Mulberry St, Scranton, PA 18510

Open in the dashboard

General payments

$7,161

471 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jordyn O'Leary of Scranton, PA is reported in the CMS Open Payments database as having received $7,161 across 471 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,228 88
2024 General $1,184 66
2023 General $1,247 81
2022 General $1,261 80
2021 General $2,240 156

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jordyn O'Leary
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jordyn O'Leary were reported at $1,228. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jordyn O'Leary Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,240 $132 $37–$438 $132
2022 $1,261 $155 $48–$522 $149
2023 $1,247 $167 $52–$557 $160
2024 $1,184 $178 $55–$600 $164
2025 $1,228 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $900 65 payments
  2. ITI, Inc. $802 48 payments
  3. Janssen Pharmaceuticals, Inc $738 56 payments
  4. Alkermes, Inc. $530 28 payments
  5. Otsuka America Pharmaceutical, Inc. $484 28 payments
  6. Neurocrine Biosciences, Inc. $482 41 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $463 36 payments
  8. Teva Pharmaceuticals USA, Inc. $431 24 payments
  9. Bausch Health US, LLC $359 17 payments
  10. Axsome Therapeutics, Inc. $243 13 payments
  11. Other $1,729 115 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,002 469 payments
  2. Education $158 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $675 45 payments
  2. CAPLYTA $608 32 payments
  3. INVEGA SUSTENNA $540 41 payments
  4. ARISTADA Cns $485 26 payments
  5. ARISTADA Cns $485 26 payments
  6. LYBALVI $446 24 payments
  7. REXULTI $411 23 payments
  8. SPRAVATO $392 30 payments
  9. ARISTADA Cns $385 20 payments
  10. ARISTADA Cns $385 20 payments
  11. Other $5,246 360 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 71 drugs

Part D claims

4,605

Median for Physician Assistant: 241

Drug cost

$1,210,087

Median for Physician Assistant: $4,110

Branded share of claims

23.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 17 $246,151
Tasimelteon Generic 12 $162,897
Austedo Xr Deutetrabenazine Brand 19 $150,126
Vraylar Cariprazine Hcl Brand 104 $135,670
Rexulti Brexpiprazole Brand 72 $103,506
Austedo Deutetrabenazine Brand 13 $94,711
Nuplazid Pimavanserin Tartrate Brand 17 $85,556
Nuedexta Dextromethorphan Hbr/Quinidine Brand 13 $25,848
Abilify Maintena Aripiprazole Brand 11 $23,159
Caplyta Lumateperone Tosylate Brand 14 $21,547

The 10 drugs with the highest cost, of 71 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$19,916

Medicare's payments for the services billed

Medicare patients

94

Average age 61

Services billed

327

61 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 60%
Arthritis 39%
Diabetes 24%
Chronic kidney disease 20%
Alzheimer's or dementia 16%
Ischemic heart disease 15%
COPD 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $162
  • Lundbeck LLC $142
$305 72 —
Auvelity
  • Axsome Therapeutics, Inc. $154
$154 — —
CAPLYTA
  • ITI, Inc. $133
$133 14 —
ARISTADA
  • Alkermes, Inc. $74
$74 11 —
APLENZIN
  • Bausch Health US, LLC $64
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

471 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record